19th Oct 2016 08:00
19 October 2016
Director's Share Dealing
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services group, announces that it was notified on 18 October 2016 that the following transactions took place on 18 October 2016.
Shaun Chilton, the Group Chief Executive Officer-designate, has exercised a total of 206,389 nil cost options over ordinary shares of 0.1 pence each in the Company. The options have been satisfied by shares from the Clinigen Group Employment Benefit Trust. He has subsequently sold 97,246 ordinary shares of 0.1 pence each in the Company at a price of 750 pence per share in order to meet the expected tax obligations.
Following these transactions, Mr Chilton's total beneficial interest in the Company is 412,943 ordinary shares representing approximately 0.36 per cent of the current issued share capital.
Separately, Peter George, the Group Chief Executive Officer, sold 2,200,000 ordinary shares of 0.1 pence each in the Company at a price of 750 pence per share.
Following these transactions, Mr George's total beneficial interest in the Company is 3,357,242 ordinary shares, representing approximately 2.93 per cent of the current issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Shaun Chilton | |
2 | Reason for the notification | ||
a) | Position/status | Group Chief Executive Officer-designate | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | N/A | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | 1. The exercise of 206,389 options over ordinary shares in the Company following the vesting of an award granted under the Long Term Incentive Plan. 2. The sale of 97,246 ordinary shares in the Company made in order to meet expected tax obligations arising from the transaction described in 1. | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
750p | 97,246 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
97,246 750p £729,345 | |
f) | Date of the transaction | 18 October 2016 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Peter George | |
2 | Reason for the notification | ||
a) | Position/status | Group Chief Executive Officer | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | N/A | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | Sale of shares | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
750p | 2,200,000 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
2,200,000 750p £16,500,000 | |
f) | Date of the transaction | 18 October 2016 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
-Ends-
Contact Details
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Peter George, Group Chief Executive Officer | |
Shaun Chilton, Group Chief Executive Officer - designate Martin Abell, Group Chief Financial Officer | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser)James Black / Tom Ballard (Corporate Broking) | |
| |
Peel Hunt LLP - Joint Broker | Tel: +44 (0) 20 7418 8900 |
James Steel / Dr Christopher Golden | |
Instinctif Partners (media relations) | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Jayne Crook / Emma Barlow | Email: [email protected] |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.
For more information, please visit www.clinigengroup.com
Related Shares:
CLIN.L